Matthew Vincent Dolan - Sep 1, 2022 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
SVP Corporate Strategy-Develop
Signature
By: Jereme Sylvain For: Matthew V Dolan
Stock symbol
DXCM
Transactions as of
Sep 1, 2022
Transactions value $
-$408
Form type
4
Date filed
9/6/2022, 09:33 AM
Previous filing
Mar 17, 2022
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Sale -$408 -5 -0.02% $81.63 26.5K Sep 1, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2 Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 26,536 unvested restricted stock units, 11,556 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,192 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,788 of which were granted on March 8, 2020 and shall vest through March 8, 2023.